Schizophrenia MedDRA version: 12.1 Level: LLT Classification code 10039626 Term: Schizophrenia
Conditions
Sponsors
Eli Lilly and Company
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Patients are male or female, 18 to 65 years of age (inclusive) at study entry, with a diagnosis of schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; APA 2000) (Disorganized, 295.10; Catatonic, 295.20; Paranoid 295.30; or Undifferentiated, 295.90) and confirmed by the Structured Clinical Interview for DSM-IV-TR (SCID). [2] Female patients of childbearing potential must test negative for pregnancy at Visit 1 and agree to use a single, effective, medically acceptable method of birth control, specifically: an oral contraceptive combined pill; an implantable contraceptive; an injectable contraceptive; a contraceptive patch (for women =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: [12] Have any other current Axis I psychiatric diagnoses (as defined in DSM-IV-TR) in addition to schizophrenia. [15] Patients who have a history of an inadequate clinical response, in the opinion of the investigator, to antipsychotic treatment for schizophrenia. [16] Patients who require concomitant treatment with any other medication with primary central nervous system activity, other than those allowed as specified in Section 9.8 and Attachment 3, or with any other medication specifically excluded in Attachment 3. [17] Patients who have received treatment with any depot formulation of an antipsychotic medication within 1 dosing interval, minimum of 4 weeks, prior to Visit 1. [18] Patients have answered ‘yes’ to either Question 4 or Question 5 (on the "Suicidal Ideation" portion of the C–SSRS, or answer "yes" to any of the suicide-related behaviors on the "Suicidal Behavior" portion of the C–SSRS; and the ideation or behavior occurred within the past month. [19] DSM-IV-TR diagnosis of substance dependence or substance abuse (except nicotine and caffeine) within the 6 months prior to Visit 1. [20] Diagnosis of substance-induced psychosis by DSM-IV-TR criteria within 7 days of Visit 1 (or at any time during the study). [21] Female patients who are pregnant, nursing, or who intend to become pregnant within 30 days of completing the study. [22] Have known, uncorrected, narrow-angle glaucoma. [23] Have a history of one or more seizures except for either of the following 2 situations: • A single simple febrile seizure between ages 6 months and 5 years (a single simple febrile seizure is defined as lacking focality and lasting less than 15 minutes, not associated with a central nervous system (CNS) infection or severe metabolic disturbance) • A single seizure with an identifiable etiology, which has been completely resolved. Note: The site must contact the sponsor or its representatives prior to entering a patient who has experienced any seizure. [30] Patients with acute, serious, or unstable medical conditions, [32] Patients with a corrected QT interval (Bazett’s; QTcB) >450 msec (male) or >470 msec (female) at Visit 1 (based on the central vendor’s ECG overread). [34] Patients with moderate to severe renal impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): Change from baseline in body weight during the double-blind treatment phase;Main Objective: The primary objective of this study is to test the hypothesis that mean weight gain, as assessed by change from baseline, will be statistically significantly less for flexibly dosed LY2140023 (20, 40, or 80 mg BID) than for flexibly dosed aripiprazole (10, 15, or 30 mg/day) in patients with schizophrenia after 24 weeks of double-blind treatment.;Secondary Objective: The main secondary objectives are as follows, please refer to the Protocol Section 6.2 for further details. •To test the hypothesis that the proportion of patients with potentially clinically significant weight gain, will be statistically significantly less for LY2140023 than for aripiprazole after 24 weeks of double-blind treatment. •To evaluate the safety and tolerability of LY2140023 compared with aripiprazole •To evaluate the efficacy of LY2140023 compared with aripiprazole •To evaluate the efficacy of LY2140023 compared with aripiprazole within a prospectively defined genetic subgroup •To assess whether LY2140023 demonstrates improvement compared with aripiprazole on health outcomes, including quality of life and functioning •To further evaluate efficacy, safety, and tolerability of LY2140023 through assessment of all efficacy and safety measures at the end of the 28-week open-label phase. | — |
Countries
Austria, Germany, Poland, Spain
Outcome results
None listed